BioCentury
ARTICLE | Clinical News

MG98: Phase II

July 15, 2002 7:00 AM UTC

In a North American Phase II trial, twice-weekly MG98 failed to give an objective clinical response in RCC patients. BBG has European rights to MG98 under a February deal with MethylGene. MOGN has U.S...